NovaGo Therapeutics is a Swiss biotech company focused on human antibody therapeutics targeting nerve growth and regeneration to enhance functional recovery following spinal cord injury. Phase 1 clinical trials for the treatment of spinal cord injury are expected to start in 2023.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business